| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $196,731 | 4 | 100 |
Sells | $0 | 0 | 0 |
| Hitchcock Michael J.M. | Interim CEO | 1 | $99,180 | 0 | $0 | $99,180 |
| Erdtmann Rainer M | See Remarks | 3 | $97,551 | 0 | $0 | $97,551 |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for …
Over the last 12 months, insiders at Biomea Fusion, Inc. have bought $196,731 and sold $0 worth of Biomea Fusion, Inc. stock.
On average, over the past 5 years, insiders at Biomea Fusion, Inc. have bought $3.23M and sold $13.28M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hitchcock Michael J.M. (Interim CEO) — $99,180. Erdtmann Rainer M (See Remarks) — $97,551.
The last purchase of 30,000 shares for transaction amount of $42,999 was made by Erdtmann Rainer M (See Remarks) on 2025‑12‑11.
| 2025-12-11 | Erdtmann Rainer M | See Remarks | 30,000 0.0475% | $1.43 | $42,999 | -12.50% | ||
| 2025-12-02 | Hitchcock Michael J.M. | Interim CEO | 100,000 0.1741% | $0.99 | $99,180 | +38.93% | ||
| 2025-12-01 | Erdtmann Rainer M | See Remarks | 10,000 0.0175% | $1.05 | $10,500 | +31.68% | ||
| 2025-11-28 | Erdtmann Rainer M | See Remarks | 40,000 0.0682% | $1.10 | $44,052 | +22.02% | ||
| 2024-09-30 | Hitchcock Michael J.M. | director | 10,000 0.029% | $10.06 | $100,600 | -75.20% | ||
| 2024-06-11 | Valle Franco | Chief Financial Officer | 12,509 0.0348% | $4.43 | $55,361 | +1.92% | ||
| 2023-06-01 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 50,000 0.1638% | $34.56 | $1.73M | -57.49% | |
| 2023-05-31 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 75,000 0.2524% | $33.81 | $2.54M | -55.29% | |
| 2023-05-12 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 25,000 0.0841% | $33.84 | $846,000 | -53.59% | |
| 2023-05-09 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 150,000 0.5185% | $34.50 | $5.18M | -53.05% | |
| 2023-05-08 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 100,000 0.3445% | $33.99 | $3.4M | -52.35% | |
| 2023-04-20 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 200,000 0.6723% | $29.12 | $5.82M | -43.68% | |
| 2023-03-31 | Sale | A2A Pharmaceuticals, Inc. | 10 percent owner | 200,000 0.6812% | $31.25 | $6.25M | -45.45% | |
| 2023-03-30 | Chen Bihua | 400,000 1.2695% | $30.00 | $12M | -47.02% | |||
| 2022-11-14 | Hitchcock Michael J.M. | director | 5,000 0.0169% | $7.93 | $39,650 | +88.58% | ||
| 2022-11-11 | Valle Franco | Chief Financial Officer | 4,100 0.0134% | $7.63 | $31,286 | +90.83% | ||
| 2022-08-16 | A2A Pharmaceuticals, Inc. | 30,684 0.1067% | $13.87 | $425,648 | -9.55% | |||
| 2022-07-21 | Sale | A2A Pharmaceuticals, Inc. | 34,658 0.1118% | $11.21 | $388,516 | -2.11% | ||
| 2022-06-24 | Sale | A2A Pharmaceuticals, Inc. | 34,658 0.1168% | $11.76 | $407,578 | -5.69% | ||
| 2022-01-14 | Valle Franco | Chief Financial Officer | 10,000 0.033% | $8.68 | $86,767 | -17.39% |
| Erdtmann Rainer M | See Remarks | 723027 1% | $451,024.24 | 7 | 0 | <0.0001% |
| Hitchcock Michael J.M. | Interim CEO | 115000 0.1591% | $71,737.00 | 3 | 0 | +6.69% |
| Stergiopoulos Sotirios | director | 4400000 6.0858% | $2.74M | 1 | 0 | <0.0001% |
| Chen Bihua | 3570872 4.939% | $2.23M | 2 | 0 | <0.0001% | |
| A2A Pharmaceuticals, Inc. | 10 percent owner | 3500000 4.841% | $2.18M | 2 | 9 | <0.0001% |
| Butler Thomas Andrew | CEO | 228470 0.316% | $142,519.59 | 4 | 0 | <0.0001% |
| Valle Franco | Chief Financial Officer | 42500 0.0588% | $26,511.50 | 3 | 0 | +25.12% |
$2,542,362 | 111 | 11.81% | $36.83M | |
$156,891,025 | 80 | -24.91% | $36.3M | |
$84,911,583 | 59 | 17.82% | $37.44M | |
$693,326 | 47 | -16.24% | $40.24M | |
$6,204,522 | 45 | 1.91% | $36.5M |
| Increased Positions | 26 | +27.66% | 5M | +19.42% |
| Decreased Positions | 38 | -40.43% | 7M | -26.71% |
| New Positions | 8 | New | 959,983 | New |
| Sold Out Positions | 20 | Sold Out | 5M | Sold Out |
| Total Postitions | 82 | -12.77% | 23M | -7.29% |
| Fmr Llc | $10,207.00 | 10.73% | 7.62M | +372,940 | +5.15% | 2025-09-30 |
| Cormorant Asset Management, Lp | $4,785.00 | 5.03% | 3.57M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $2,908.00 | 3.06% | 2.17M | +290,376 | +15.45% | 2025-09-30 |
| Aisling Capital Management Lp | $2,745.00 | 2.89% | 2.05M | 0 | 0% | 2025-09-30 |
| Heights Capital Management, Inc | $1,926.00 | 2.03% | 1.44M | -2M | -62.55% | 2025-09-30 |
| Woodline Partners Lp | $1,743.00 | 1.83% | 1.3M | -443,000 | -25.4% | 2025-09-30 |
| Blackrock, Inc. | $1,208.00 | 1.27% | 901,555 | +148,004 | +19.64% | 2025-09-30 |
| Renaissance Technologies Llc | $799.00 | 0.84% | 595,900 | +595,900 | New | 2025-09-30 |
| Federated Hermes, Inc. | $767.00 | 0.81% | 572,043 | -4,321 | -0.75% | 2025-09-30 |
| Two Sigma Investments, Lp | $754.00 | 0.79% | 562,968 | +213,321 | +61.01% | 2025-09-30 |